A practical reference on phase 2 trial: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-06 and is reviewed periodically as new material appears.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Only at some distance does convection occur to carry heat to the bulb's envelope. The orientation of the filament influences efficiency. Gas flow parallel to the filament, e.g., a vertically oriented bulb with vertical (or axial) filament, reduces convective losses. The efficiency of the lamp increases with a larger filament diameter. Thin-filament, low-power bulbs benefit less from a fill gas, so are often only evacuated. Early light bulbs with carbon filaments also used carbon monoxide, nitrogen, or mercury vapor. However, carbon filaments operate at lower temperatures than tungsten ones, so the effect of the fill gas was not significant as the heat losses offset any benefits.
=== Superabsorbent polymers === One area of aspartic acid market growth is biodegradable superabsorbent polymers (SAP), and hydrogels. Around 75% of superabsorbent polymers are used in disposable diapers and an additional 20% is used for adult incontinence and feminine hygiene products. Polyaspartic acid, the polymerization product of aspartic acid, is a biodegradable substitute to polyacrylate.
{\displaystyle {\begin{aligned}\sigma _{xx}&=-{\frac {2P}{\pi }}{\frac {x^{2}z}{\left(x^{2}+z^{2}\right)^{2}}}\\\sigma _{zz}&=-{\frac {2P}{\pi }}{\frac {z^{3}}{\left(x^{2}+z^{2}\right)^{2}}}\\\sigma _{xz}&=-{\frac {2P}{\pi }}{\frac {xz^{2}}{\left(x^{2}+z^{2}\right)^{2}}}\end{aligned}}}
The numerous added equipment and consumables for the day-long mission boosted the weight of Faith 7 considerably; it now weighed over 3,000 pounds (1,400 kg). On March 15, the Atlas was rolled out of the factory a second time and passed tests with flying colors; Convair engineers expressed confidence that this "was their best bird yet." The booster actuators were offset slightly to prevent a recurrence of the liftoff roll transient that occurred on Mercury-Atlas 8. Several minor modifications were made to 130D as a result of postflight findings from failed Atlas launches over the previous year. These included adding a plastic liner to the inside of the turbopumps to prevent the turbine blades from rubbing against the casing and triggering an explosion from a friction spark, improvements to the wiring of the programmer, and additional steps taken to prevent the possibility of a fire breaking out in or around the thrust section. The upgraded MA-2 engines featured baffled injector heads and a hypergolic igniter, eliminating any concerns of rough combustion or the need for hold-down time prior to liftoff. As such, the RCC (Rough Combustion Cutoff) sensors on 130D were operated open loop and for qualitative purposes only. The propellant conserved by not performing the three second hold-down time would allow a longer booster burn. On Mercury-Atlas 8, 112 gallons of fuel were removed prior to launch and so an extended burn was not possible even with eliminating the hold-down, but on this flight there would be enough propellant to extend burn time.
Absolute numbers vary between pets, and with meter calibrations. Glucometers made for humans are generally accurate using feline blood except when reading lower ranges of blood glucose (<80 mg/dl–4.44 mmol/L). At this point the size difference in human and animal red blood cells can create inaccurate readings.
Sources: en.wikipedia.org
ICT appears to be vanishing as a result of greater genetic diversity within the affected populations in conjunction with educational programs to ensure that tinned cooking utensils are used instead of copper pots and pans being directly exposed to cooked foods. The preponderance of cases of early childhood cirrhosis identified in Germany over a period of 10 years were not associated with either external sources of copper or with elevated hepatic metal concentrations Only occasional spontaneous cases of ICT arise today.
With Esther Snyder's death in 2006 at the age of 86, the presidency passed to Mark Taylor, former vice president of operations. Taylor became the company's fifth president and first non-family member to hold the position, although he did have ties to the family. The company's current heiress is Lynsi Snyder, daughter of Guy and only grandchild of Esther and Harry Snyder. Snyder, who was 23 years old and known as Lynsi Martinez at her grandmother's death, owns the company through a trust. She gained control of 50% of the company in 2012 when she turned 30, and nearly full control at 35 in May 2017.
Dysfunctional structure of one particular laminin, laminin-211, is the cause of one form of congenital muscular dystrophy. Laminin-211 is composed of α2, β1, and γ1 chains. This laminin's distribution includes the brain and muscle fibers. In muscle, it binds to alpha-dystroglycan and integrin alpha7—beta1 via the G domain, and via the other end, it binds to the extracellular matrix. Abnormal laminin-332, essential for epithelial cell adhesion to the basement membrane, leads to junctional epidermolysis bullosa, characterized by generalized blisters, exuberant granulation tissue of the skin and mucosa, and pitted teeth. Malfunctional laminin-521 in the kidney filter causes leakage of protein into the urine and nephrotic syndrome.
In the balanced budget for the 2019–20 fiscal year, worth $40 billion, the State of Illinois authorized more spending on education, including grade schools, community colleges, and state universities. Funding for grade schools rose by nearly $379 million, more than the $29 million required by the new state funding for education formula passed the previous year. Funding for community colleges increased by $14 million, and funding for public universities by $53 million. Grants for low-income students received a $50-million bump. The Illinois Department of Children and Family Services, facing financial pressure, received $80 million for hiring new staff and improving services. Moreover, the Rebuild Illinois capital plan spent $3.2 billion on public colleges and universities over six years. Pritzker created the College Student Credit Card Marketing and Debt Task Force (House Bill 1581), whose task it is to look for ways to help students reduce their credit card debts after graduation from an institution of higher education in the state. The task force was to report its findings to the General Assembly by December 4, 2019. Pritzker created a job training program for community colleges funded based on the percentage of low-income students attending. It launched in 2020. In July 2019, Pritzker signed House Bill 2512. Approved unanimously by both chambers of the Illinois General Assembly, it requires state universities to report what students pay in tuition fees to the Illinois Board of Higher Education. This is intended to increase transparency in the costs of higher education.
Sources: en.wikipedia.org
==== Typical examples of patterns ==== For each of the functional entities (qi, xuĕ, zàng-fǔ, meridians etc.), typical disharmony patterns are recognized; for example: qi vacuity and qi stagnation in the case of qi; blood vacuity, blood stasis, and blood heat in the case of xuĕ; Spleen qi vacuity, Spleen yang vacuity, Spleen qi vacuity with down-bearing qi, Spleen qi vacuity with lack of blood containment, cold-damp invasion of the Spleen, damp-heat invasion of Spleen and Stomach in case of the Spleen zàng; wind/cold/damp invasion in the case of the meridians. TCM gives detailed prescriptions of these patterns regarding their typical symptoms, mostly including characteristic tongue and/or pulse findings. For example:
Total destruction of life. Destruction of only intelligent life. Degeneration. Loss of interest. However, he refuses to see these as inevitable ends. But the assumption that the only limit to the development of a civilization can be the existence of a finite amount of information, in all areas, is also false, since it is highly improbable that information in the Universe is infinite. Given these two hypotheses, Kardashev argues that there is no universal civilization (supercivilization) because highly developed civilizations lose interest in space exploration. In any case, and despite the problem of the end of civilizations, he concludes, in the light of his functional definition of the advanced civilization, that the latter must use mass and energy on fantastic scales. According to him, there is no reason to denounce the hypothesis that the expansion of the Universe would not be an effect of the intelligent activity of a supercivilization.
The IDF's mission is to "defend the existence, territorial integrity and sovereignty of the state of Israel. To protect the inhabitants of Israel and to combat all forms of terrorism which threaten the daily life." The Israeli military's primary principles derive from Israel's need to combat numerically superior opponents. One such principle, is the concept that Israel cannot afford to lose a single war. The IDF believes that this is possible if it can rapidly mobilize troops to insure that they engage the enemy in enemy territory. In the 21st century, various nonconventional threats including terrorist organizations, subterranean infrastructure operated by Hamas, etc. have forced the IDF to modify its official defense doctrine.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。